Last reviewed · How we verify
Transdermal Buprenorphine
At a glance
| Generic name | Transdermal Buprenorphine |
|---|---|
| Also known as | no other intervention |
| Sponsor | Taiwan Mundipharma Pharmaceuticals Ltd. |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- ACTION: Trial of Adding Buprenorphine, CBT, and TMS to Improve Outcomes of Long-Term Opioid Therapy for Chronic Pain (PHASE1, PHASE2)
- Transdermal Patch for BupRenorphine Induction DurinG PrEgnancy (Patch BRIDGE) (PHASE3)
- Buprenorphine as a Post-operative Analgesic in Opioid-Naive Patients After Ankle Fracture Surgery (PHASE4)
- Transdermal Buprenorphine for the Treatment of Radiation-Induced Mucositis Pain in Head and Neck Cancer Patients (PHASE2)
- An Exploratory Clinical Study of a Low-dose Buprenorphine Patch for the Treatment of Autism Spectrum Disorders (NA)
- Comparative Efficacy of Buprenorphine Transdermal Patch Versus Tramadol in Postoperative Analgesia for Shoulder Arthroscopy (PHASE4)
- Transdermal Buprenorphine Patch for Laparoscopic Cholecystectomy (NA)
- Improved Pain Management in Knee Osteoarthritis-related Surgeries
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |